Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi
Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals in a transaction that values the U
Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorde
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh